Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,815,942

« Back to Dashboard
Patent 7,815,942 protects AZILECT and is included in one NDA. There has been one Paragraph IV challenge on Azilect. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has twenty-three patent family members in sixteen countries.

Summary for Patent: 7,815,942

Title:Rasagiline formulations of improved content uniformity
Abstract:Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.
Inventor(s): Peskin; Tirtza Berger (Raanana, IL)
Assignee: Teva Pharmaceutical Industries, Ltd. (Petach Tikva, IL)
Application Number:11/359,324
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 43rd percentile
Forward Citations: 13th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
rasagiline mesylate
TABLET;ORAL021641-001May 16, 2006RXNo7,815,942Aug 27, 2027YY TREATMENT OF PARKINSON'S DISEASE
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006RXYes7,815,942Aug 27, 2027YY TREATMENT OF PARKINSON'S DISEASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,815,942

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Iceland8669<disabled in preview>
Japan2008531572<disabled in preview>
Japan5738509<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.